Project description
Multifaceted oncolytic virus-based approach for cancer immunotherapy
Although immunotherapy has recently emerged as a promising approach to treat cancer, clinical responses, especially in solid tumours, have been disappointing. Hepatocellular carcinoma (HCC) is particularly challenging due to the inherently immune-suppressive microenvironment of the liver. To address this, the EU-funded ONCO-VAX project will use oncolytic viruses (OVs) to directly lyse tumour cells, as an integral part of a multi-faceted dendritic cell vaccine approach to stimulate immune responses against HCC. To overcome potential innate antiviral immune responses, scientists will characterize changes in the tumor microenvironment in response to OV therapy, and use this information to engineer new vectors to express genes that restrict immune suppression. Additional features are expected to elicit a broad and life-long immunity against the tumour.
Fields of science
Topic(s)
Call for proposal
ERC-2019-STG
See other projects for this call
Funding Scheme
ERC-STG - Starting GrantHost institution
81675 Muenchen
Germany
Beneficiaries (1)
81675 Muenchen